Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
出版年份 2022 全文链接
标题
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
作者
关键词
-
出版物
KIDNEY INTERNATIONAL
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-10-19
DOI
10.1016/j.kint.2022.09.017
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
- (2022) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis
- (2021) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
- (2021) Brad H. Rovin et al. KIDNEY INTERNATIONAL
- Why Target the Gut to Treat IgA Nephropathy?
- (2020) Jonathan Barratt et al. Kidney International Reports
- Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
- (2019) Aliza Thompson et al. Clinical Journal of the American Society of Nephrology
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
- (2019) Lesley A. Inker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy
- (2018) Jan Novak et al. SEMINARS IN NEPHROLOGY
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy
- (2017) Jicheng Lv et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
- (2017) Bengt C Fellström et al. LANCET
- New insights into the pathogenesis of IgA nephropathy
- (2017) See Cheng Yeo et al. PEDIATRIC NEPHROLOGY
- Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis
- (2016) Lesley A. Inker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
- (2015) Thomas Rauen et al. NEW ENGLAND JOURNAL OF MEDICINE
- GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
- (2014) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- IgA Nephropathy
- (2013) Robert J. Wyatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort
- (2012) Michelle Petri et al. ARTHRITIS AND RHEUMATISM
- An update on the pathogenesis and treatment of IgA nephropathy
- (2012) Joanna K. Boyd et al. KIDNEY INTERNATIONAL
- The Pathophysiology of IgA Nephropathy
- (2011) H. Suzuki et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria
- (2011) H. K. Smerud et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started